Tender Offer | ₹800.00 Crores | Listed at BSE, NSE | Thu, Apr 23, 2026 - Wed, Apr 29, 2026
Aurobindo Pharma Ltd Buyback is a tender offer for the repurchase of up to 0.54 crore equity shares at a buyback price of ₹1475 per share with a face value of ₹10 per share, aggregating to ₹800.00 crores.
The record date for determining eligible shareholders is Apr 17, 2026. Shareholders holding equity shares as on the record date are eligible to participate in the buyback.
The buyback opens on Apr 23, 2026 and closes on Apr 29, 2026, with the last date for receipt of tender forms being Apr 29, 2026.
The finalisation of buyback acceptance is expected on May 7, 2026, followed by settlement of bids on May 7, 2026.
Axis Capital Ltd. is the Manager to the Buyback, Kfin Technologies Ltd. is the Registrar and Axis Capital Limited is the Registered Broker to the Buyback.
Investors are advised to refer to the Aurobindo Pharma Ltd Letter of Offer for detailed information, including eligibility criteria, entitlement ratio, acceptance methodology, and tax implications.
Offer Opening Date
Thu, Apr 23, 2026
Offer Closing Date
Wed, Apr 29, 2026
Buyback Price
₹1475 per share
Record Date
April 17, 2026
| Category | Entitlement Ratio | Shares Offered |
|---|---|---|
| Small Shareholders | 7 : 61 | 8,13,560 |
| General Category | 2 : 249 | 46,10,168 |
Note:
Small Shareholders are retail shareholders under SEBI regulations.
General Category includes all other eligible shareholders.
Entitlement ratio is based on fully paid-up equity shares held on the record date.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 49,784.97 | 45,071.51 | 39,889.99 |
| Total Income | 32,345.58 | 29,559.25 | 25,145.97 |
| Profit After Tax | 1,582.72 | 1,211.02 | 684.85 |
| EBITDA | 6,605.00 | 5,843.00 | 3,758.00 |
| NET Worth | 32,647.00 | 29,851.00 | |
| Reserves and Surplus | 20,476.03 | 19,664.23 | 17,975.44 |
| Amount in ₹ Crore | |||
Aurobindo Pharma Ltd. is a leading Indian multinational pharmaceutical company headquartered in HITEC City, Hyderabad, founded in 1986.
It specializes in manufacturing generic pharmaceuticals, active pharmaceutical ingredients (APIs), and formulations, ranking among the top 10 generic pharma companies globally.
The company has extensive expertise in Semi-Synthetic Penicillins (SSP), anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics.
The company's operations span over 155 countries, with significant sales and operations in the USA, Europe, and emerging markets.
The company has a diverse portfolio spanning API, formulations, biosimilars, dermatology, respiratory, injectables, and vaccines.
The company operates 29+ manufacturing plants and 9 R&D centres—major regulatory bodies, including the US FDA, UK MHRA, and WHO, approve many facilities.
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Mar-2026 | 1,330.90 | 1,180.00 | 1,272.16 |
| Feb-2026 | 1,250.85 | 1,106.25 | 1,179.45 |
| Jan-2026 | 1,270.40 | 1,115.80 | 1,176.03 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Mar-2026 | 1,330.00 | 1,179.80 | 1,272.09 |
| Feb-2026 | 1,250.90 | 1,106.00 | 1,179.10 |
| Jan-2026 | 1,270.80 | 1,116.20 | 1,175.87 |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Aurobindo Pharma Ltd
Plot No. 2
Maithrivihar
Ameerpet,
Hyderabad, Telangana, 500038
Lead Manager(s)
Registered Broker
The Aurobindo Pharma Buyback 2026 opens on April 23, 2026, and closes on April 29, 2026.
Last date to be eligible to participate in buyback is April 16, 2026.
The Aurobindo Pharma Buyback 2026 is a Tender Offer.
Aurobindo Pharma Buyback 2026 Schedule
| Buyback Opening Date | April 23, 2026 |
| Buyback Closing Date | April 29, 2026 |
| Last Date for receipt of Tender Forms | April 29, 2026 |
| Finalisation of Buyback Acceptance | May 7, 2026 |
| Last Date for settlment of bids | May 7, 2026 |
| Last Date for Extinguishment of Shares | May 18, 2026 |
The Aurobindo Pharma Buyback 2026 is being offered at Rs ₹1475 per share.
| Category | Entitlement Ratio | Shares Offered |
|---|---|---|
| Small Shareholders | 7 : 61 | 8,13,560 |
| General Category | 2 : 249 | 46,10,168 |
Note:
Small Shareholders are retail shareholders under SEBI regulations.
General Category includes all other eligible shareholders.
Entitlement ratio is based on fully paid-up equity shares held on the record date.
The issue size of Aurobindo Pharma Buyback 2026 is 54,23,728 equity shares at ₹1475 per share aggregating up to ₹800.00 Crores.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.
The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.
The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.
The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.
The Aurobindo Pharma Buyback 2026 offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.
